Is chemical synthetic accessibility computationally predictable for drug and lead-like molecules? A comparative assessment between medicinal and computational chemists

European Journal of Medicinal Chemistry

Volumn 54, Issue , 2012, Pages 679-689

  Bonnet, Pascal ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

De novo design; Drug discovery; Synthesis design; Synthetic accessibility; Virtual screening

Indexed keywords

LEAD; MOLECULAR SCAFFOLD;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPUTER ANALYSIS; COMPUTER PROGRAM; PREDICTION; SYNTHESIS;

CHEMISTRY TECHNIQUES, SYNTHETIC; CHEMISTRY, PHARMACEUTICAL; COMPUTERS; DATABASES, CHEMICAL; DRUG APPROVAL; DRUG DISCOVERY; PHARMACEUTICAL PREPARATIONS;

EID: 84864397164     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.06.024     Document Type: Article

References (60)

1. W.R. Pitt, D.M. Parry, B.G. Perry, and C.R. Groom Heteroaromatic rings of the future J. Med. Chem. 52 2009 2952 2963
2. K.V. Dorschner, D. Toomey, M.P. Brennan, T. Heinemann, F.J. Duffy, K.B. Nolan, D. Cox, M.F.A. Adamo, and A.J. Chubb TIN - a combinatorial compound collection of synthetically feasible multicomponent synthesis products J. Chem. Inf. Model. 51 2011 986 995
3. T. Fink, and J.-L. Reymond Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery J. Chem. Inf. Model. 47 2007 342 353 (Pubitemid 46615939)
4. L.C. Blum, and J.-L. Reymond 970 Million druglike small molecules for virtual screening in the chemical universe database GDB-13 J. Am. Chem. Soc. 131 2009 8732 8733
5. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26 (Pubitemid 33653411)
6. H. Bohm The computer program LUDI: a new method for the de novo design of enzyme inhibitors J. Comput. Aided Mol. Des. 6 1992 61 78
7. R.-X. Wang, Y. Gao, and L.-L. Lai LigBuilder: a multi-purpose program for structure-based drug design J. Mol. Model. 6 2000 498 516
8. Y. Yuan, J. Pei, and L. Lai LigBuilder 2: a practical de novo drug design approach J. Chem. Inf. Model. 51 2011 1083 1091
9. S. Firth-Clark, H.M.G. Willems, A. Williams, and W. Harris Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen J. Chem. Inf. Model. 46 2006 642 647
10. M. Eisen, D. Wiley, M. Karplus, and R. Hubbard HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site Proteins: Struct., Funct., Bioinf. 19 1994 199 221 (Pubitemid 24215048)
11. A. Pierce, G. Rao, and G. Bemis BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease J. Med. Chem. 47 2004 2768 2775 (Pubitemid 38656730)
12. V. Gillet, A. Johnson, P. Mata, S. Sike, and P. Williams SPROUT: a program for structure generation J. Comput.-Aided Mol. Des. 7 1993 127 153
13. K. Boda, and A.P. Johnson Molecular complexity analysis of de novo designed ligands J. Med. Chem. 49 2006 5869 5879 (Pubitemid 44484933)
14. J. Degen, and M. Rarey FLEXNOVO: structure-based searching in large fragment spaces ChemMedChem 1 2006 854 868 (Pubitemid 44384546)
15. Q. Huang, L.-L. Li, S.-Y. Yang, and Q. Huang PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility J. Mol. Graphics Model. 28 2010 775 787
16. R. Barone, and M. Chanon A new and simple approach to chemical complexity. Application to the synthesis of natural products J. Chem. Inf. Comput. Sci. 41 2001 269 272 (Pubitemid 32408637)
17. C. Rücker, G. Rücker, and S.H. Bertz Organic synthesis - art or science? J. Chem. Inf. Comput. Sci. 44 2004 378 386
18. T.K. Allu, and T.I. Oprea Rapid evaluation of synthetic and molecular complexity for in silico chemistry J. Chem. Inf. Model. 45 2005 1237 1243 (Pubitemid 41476007)
19. V. Gillet, G. Myatt, Z. Zsoldos, and A. Johnson SPROUT, HIPPO and CAESA: tool for de novo structure generation and estimation of synthetic accessibility Perspect. Drug Discovery Des. 3 1995 34 50
20. X.Q. Lewell, D.B. Judd, S.P. Watson, and M. Hann RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comput. Sci. 38 1998 511 522 (Pubitemid 128594467)
21. M. Pförtner, and M. Sitzmann J. Gasteiger, Handbook of Cheminformatics 2003 Wiley-VCH Weinheim pp. 1457-1507
22. A. Johnson, C. Marshall, and P. Judson Starting material oriented retrosynthetic analysis in the LHASA program. 1. General description J. Chem. Inf. Comput. Sci. 32 1992 411 417
23. Q. Huang, L.-L. Li, and S.-Y. Yang RASA: a rapid retrosynthesis-based scoring method for the assessment of synthetic accessibility of drug-like molecules J. Chem. Inf. Model. 51 2011 2768 2777
24. Y. Podolyan, M.A. Walters, and G. Karypis Assessing synthetic accessibility of chemical compounds using machine learning methods J. Chem. Inf. Model. 50 2010 979 991
25. K. Boda, T. Seidel, and J. Gasteiger Structure and reaction based evaluation of synthetic accessibility J. Comput.-Aided Mol. Des. 21 2007 311 325 (Pubitemid 47054812)
26. Y. Takaoka, Y. Endo, S. Yamanobe, H. Kakinuma, T. Okubo, Y. Shimazaki, T. Ota, S. Sumiya, and K. Yoshikawa Development of a method for evaluating drug-likeness and ease of synthesis using a data set in which compounds are assigned scores based on chemists' intuition J. Chem. Inf. Comput. Sci. 43 2003 1269 1275
27. M.S. Lajiness, G.M. Maggiora, and V. Shanmugasundaram Assessment of the consistency of medicinal chemists in reviewing sets of compounds J. Med. Chem. 47 2004 4891 4896 (Pubitemid 39238264)
28. P. Ertl, and A. Schuffenhauer Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions J. Cheminform. 1 2009 8
29. Web address: http://www.discoverygate.com.
30. Web address: http://pubchem.ncbi.nlm.nih.gov.
31. J.J. Irwin, and B.K. Shoichet ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 45 2005 177 182 (Pubitemid 40736970)
32. T.D. Aicher, K.R. Buszek, F.G. Fang, C.J. Forsyth, S.H. Jung, Y. Kishi, M.C. Matelich, P.M. Scola, D.M. Spero, and S.K. Yoon Total synthesis of halichondrin B and norhalichondrin B J. Am. Chem. Soc. 114 1992 3162 3164
33. A. Mullard 2010 FDA drug approvals Nat. Rev. Drug Discovery 10 2011 82 85
34. T.K. Huyck, W. Gradishar, F. Manuguid, and P. Kirkpatrick Eribulin mesylate Nat. Rev. Drug Discov. 10 2011 173 174
35. Web address: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm233863.htm.
36. K.L. Jackson, J.A. Henderson, and A.J. Phillips The halichondrins and E7389 Chem. Rev. 109 2009 3044 3079 (Washington, DC, U. S.)
37. M.J. Yu, W. Zheng, B.M. Seletsky, B.A. Littlefield, and Y. Kishi Case history: discovery of eribulin (HALAVENTM), a halichondrin B analogue that prolongs overall survival in patients with metastatic breast cancer Annu. Rep. Med. Chem. 46 2011 227 241
38. S.J. Lusher, R. McGuire, R. Azevedo, J.-W. Boiten, R.C. van Schaik, and J.A. de Vlieg A molecular informatics view on best practice in multi-parameter compound optimization Drug Discov. Today 16 2011 555 568
39. J.M. Stevenson, P.D. Mulready, Pipeline pilot 2.1, by Scitegic, J. Am. Chem. Soc. 125 (2003) 1437-1438. Pipeline Pilot 2.1 By Scitegic, 9665 Chesapeake Drive, Suite 401, San Diego, CA 92123-1365, http://www.scitegic.com.
40. Web address: http://www.prous.com/integrity (accessed 10.12.10).
41. T.I. Oprea, A.M. Davis, S.J. Teague, and P.D. Leeson Is there a difference between leads and drugs? a historical perspective J. Chem. Inf. Comput. Sci. 41 2001 1308 1315
42. G.W. Bemis, and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887 2893 (Pubitemid 26251026)
43. Web addresses: http://www.maybridge.com, https://www.sigmaaldrich.com, http://www.acros.be.
44. F. Lovering, J. Bikker, and C. Humblet Escape from flatland increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6759
45. T. Katsuki, and K.B. Sharpless The first practical method for asymmetric epoxidation J. Am. Chem. Soc. 102 1980 5974 5976
46. M.D. Hack, D.N. Rassokhin, C. Buyck, M. Seierstad, A. Skalkin, P. ten Holte, T.K. Jones, T. Mirzadegan, and D.K. Agrafiotis Library enhancement through the wisdom of crowds J. Chem. Inf. Model. 51 2011 3275 3286
47. S. Jain, S.B. Bari, and N. Rajnikant De novo design and optimization of novel inhibitor molecules for HIV integrase Int. J. ChemTech. Res. 3 2011 716 723
48. T. Sundarapandian, J. Shalini, S. Sugunadevi, and L.K. Woo Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery J. Mol. Graphics Modell. 29 2010 382 395
49. C.H.T.d.P. Da Silva, V.B. da Silva, J. Resende, P.F. Rodrigues, F.C. Bononi, C.G. Benevenuto, and C.A. Taft Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy J. Mol. Graphics Modell. 28 2010 513 523
50. A. Zaliani, K. Boda, T. Seidel, A. Herwig, C.H. Schwab, J. Gasteiger, H. Claußen, C. Lemmen, J. Degen, J. Pärn, and M. Rarey Second-generation de novo design: a view from a medicinal chemist perspective J. Comput.-Aided Mol. Des. 23 2009 593 602
51. J.B. Baell, and G.A. Holloway New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53 2010 2719 2740
52. C. Steinbeck, Y. Han, S. Kuhn, O. Horlacher, E. Luttmann, and E.L. Willighagen The chemistry development kit (CDK): an open-source java library for chemo- and bioinformatics J. Chem. Inf. Comput. Sci. 43 2003 493 500
53. D. Moffat, P. Davis, M. Hutchings, J. Davis, D. Berg, M. Batchelor, J. Johnson, J. O'Connell, R. Martin, T. Crabbe, J. Delgado, and M. Perry 4-Pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines: potent and selective inhibitors of ZAP 70 Bioorg. Med. Chem. Lett. 9 1999 3351 3356
54. P.D. Davis, D.F.C. Moffat, J.M. Davis, and M.C. Hutchings Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors Int. Pat. Appl. 1997 WO 1997/19065
55. J.-P.R.M.A. Bosmans, A.L.G. Meulemans, M.A.J. De Cleyn, and H.J.M. Gijsen Preparation of 4-(aminomethyl)piperidinebenzamides as gastrointestinal agents Int. Pat. Appl. 2000 WO 2000/037461
56. J.W.J.F. Thuring, T. Dinklo, A.S.J. Lesage, M.F.L. De Bruyn, and W. Zhuang Preparation of trisubstituted 1,2,4-triazoles and analogs as positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors Int. Pat. Appl. 2009 WO 2009/050186
57. G.J. MacDonald, J.W.J.F. Thuring, P.C. Stanislawski, W. Zhuang, Y.E.M. Van Roosbroeck, and F.A.M. Van Den Keybus Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators and their preparation Int. Pat. Appl. 2009 WO 2009/115547
58. E.J.E. Freyne, J.F.A. Lacrampe, T.P.S. Perera, P. Ten Holte, Y.A.E. Ligny, D.Y.R. Lardeau, and T. Lavrijssen Preparation of pyrazolopyrimidines as cell-cycle kinase inhibitors Int. Pat. Appl. 2006 WO 2006/074985
59. K. Van Emelen, M.G.C. Verdonck, S.F.A. Van Brandt, and L.J.J. Backx Preparation of carbonylamino derivatives as inhibitors of histone deacetylase Int. Pat. Appl. 2003 WO 2003/076395
60. K. Van Emelen Preparation of N-(piperazinylmethyl-, piperidinylmethyl- and morpholinylmethyl) sulfonamides and amides as novel inhibitors of histone deacetylase Int. Pat. Appl. 2003 WO 2003/076438, Bonnet 42